Bliss Elizabeth O'Bryhim1, Rajendra S Apte1,2,3, Nathan Kung4, Dean Coble5, Gregory P Van Stavern1,6. 1. Department of Ophthalmology and Vision Science, Washington University in St Louis, St Louis, Missouri. 2. Department of Medicine, Washington University in St Louis, St Louis, Missouri. 3. Department of Developmental Biology, Washington University in St Louis, St Louis, Missouri. 4. Blue Sky Neurology, Denver, Colorado. 5. Division of Biostatistics, Washington University in St Louis, St Louis, Missouri. 6. Department of Neurology, Washington University in St Louis, St Louis, Missouri.
Abstract
Importance: Biomarker testing for asymptomatic, preclinical Alzheimer disease (AD) is invasive and expensive. Optical coherence tomographic angiography (OCTA) is a noninvasive technique that allows analysis of retinal and microvascular anatomy, which is altered in early-stage AD. Objective: To determine whether OCTA can detect early retinal alterations in cognitively normal study participants with preclinical AD diagnosed by criterion standard biomarker testing. Design, Setting, and Participants: This case-control study included 32 participants recruited from the Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St Louis, St Louis, Missouri. Results of extensive neuropsychometric testing determined that all participants were cognitively normal. Participants underwent positron emission tomography and/or cerebral spinal fluid testing to determine biomarker status. Individuals with prior ophthalmic disease, media opacity, diabetes, or uncontrolled hypertension were excluded. Data were collected from July 1, 2016, through September 30, 2017, and analyzed from July 30, 2016, through December 31, 2017. Main Outcomes and Measures: Automated measurements of retinal nerve fiber layer thickness, ganglion cell layer thickness, inner and outer foveal thickness, vascular density, macular volume, and foveal avascular zone were collected using an OCTA system from both eyes of all participants. Separate model III analyses of covariance were used to analyze individual data outcome. Results: Fifty-eight eyes from 30 participants (53% female; mean [SD] age, 74.5 [5.6] years; age range, 62-92 years) were included in the analysis. One participant was African American and 29 were white. Fourteen participants had biomarkers positive for AD and thus a diagnosis of preclinical AD (mean [SD] age, 73.5 [4.7] years); 16 without biomarkers served as a control group (mean [SD] age, 75.4 [6.6] years). The foveal avascular zone was increased in the biomarker-positive group compared with controls (mean [SD], 0.364 [0.095] vs 0.275 [0.060] mm2; P = .002). Mean (SD) inner foveal thickness was decreased in the biomarker-positive group (66.0 [9.9] vs 75.4 [10.6] μm; P = .03). Conclusions and Relevance: This study suggests that cognitively healthy individuals with preclinical AD have retinal microvascular abnormalities in addition to architectural alterations and that these changes occur at earlier stages of AD than has previously been demonstrated. Longitudinal studies in larger cohorts are needed to determine whether this finding has value in identifying preclinical AD.
Importance: Biomarker testing for asymptomatic, preclinical Alzheimer disease (AD) is invasive and expensive. Optical coherence tomographic angiography (OCTA) is a noninvasive technique that allows analysis of retinal and microvascular anatomy, which is altered in early-stage AD. Objective: To determine whether OCTA can detect early retinal alterations in cognitively normal study participants with preclinical AD diagnosed by criterion standard biomarker testing. Design, Setting, and Participants: This case-control study included 32 participants recruited from the Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St Louis, St Louis, Missouri. Results of extensive neuropsychometric testing determined that all participants were cognitively normal. Participants underwent positron emission tomography and/or cerebral spinal fluid testing to determine biomarker status. Individuals with prior ophthalmic disease, media opacity, diabetes, or uncontrolled hypertension were excluded. Data were collected from July 1, 2016, through September 30, 2017, and analyzed from July 30, 2016, through December 31, 2017. Main Outcomes and Measures: Automated measurements of retinal nerve fiber layer thickness, ganglion cell layer thickness, inner and outer foveal thickness, vascular density, macular volume, and foveal avascular zone were collected using an OCTA system from both eyes of all participants. Separate model III analyses of covariance were used to analyze individual data outcome. Results: Fifty-eight eyes from 30 participants (53% female; mean [SD] age, 74.5 [5.6] years; age range, 62-92 years) were included in the analysis. One participant was African American and 29 were white. Fourteen participants had biomarkers positive for AD and thus a diagnosis of preclinical AD (mean [SD] age, 73.5 [4.7] years); 16 without biomarkers served as a control group (mean [SD] age, 75.4 [6.6] years). The foveal avascular zone was increased in the biomarker-positive group compared with controls (mean [SD], 0.364 [0.095] vs 0.275 [0.060] mm2; P = .002). Mean (SD) inner foveal thickness was decreased in the biomarker-positive group (66.0 [9.9] vs 75.4 [10.6] μm; P = .03). Conclusions and Relevance: This study suggests that cognitively healthy individuals with preclinical AD have retinal microvascular abnormalities in addition to architectural alterations and that these changes occur at earlier stages of AD than has previously been demonstrated. Longitudinal studies in larger cohorts are needed to determine whether this finding has value in identifying preclinical AD.
Authors: Yuchun Tsai; Bin Lu; Alexander V Ljubimov; Sergey Girman; Fred N Ross-Cisneros; Alfredo A Sadun; Clive N Svendsen; Robert M Cohen; Shaomei Wang Journal: Invest Ophthalmol Vis Sci Date: 2014-01-29 Impact factor: 4.799
Authors: Yosef Koronyo; David Biggs; Ernesto Barron; David S Boyer; Joel A Pearlman; William J Au; Shawn J Kile; Austin Blanco; Dieu-Trang Fuchs; Adeel Ashfaq; Sally Frautschy; Gregory M Cole; Carol A Miller; David R Hinton; Steven R Verdooner; Keith L Black; Maya Koronyo-Hamaoui Journal: JCI Insight Date: 2017-08-17
Authors: Flavio Nobili; Giovanni B Frisoni; Florence Portet; Frans Verhey; Guido Rodriguez; Anna Caroli; Jacques Touchon; Piero Calvini; Silvia Morbelli; Fabrizio De Carli; Ugo P Guerra; Laura A Van de Pol; Pieter-Jelle Visser Journal: J Neurol Date: 2008-08-01 Impact factor: 4.849
Authors: Susan B Bressler; Allison R Edwards; Christopher M Andreoli; Paul Andrew Edwards; Adam R Glassman; Glenn J Jaffe; Michele Melia; Jennifer K Sun Journal: Transl Vis Sci Technol Date: 2015-01-22 Impact factor: 3.283
Authors: Elizabeth Morris; Anastasia Chalkidou; Alexander Hammers; Janet Peacock; Jennifer Summers; Stephen Keevil Journal: Eur J Nucl Med Mol Imaging Date: 2015-11-28 Impact factor: 9.236
Authors: Stephen P Yoon; Dilraj S Grewal; Atalie C Thompson; Bryce W Polascik; Cynthia Dunn; James R Burke; Sharon Fekrat Journal: Ophthalmol Retina Date: 2019-03-11
Authors: Ward Fickweiler; Emily A Wolfson; Samantha M Paniagua; Marc Gregory Yu; Atif Adam; Vanessa Bahnam; Konstantina Sampani; I-Hsien Wu; Gail Musen; Lloyd P Aiello; Hetal Shah; Jennifer K Sun; George L King Journal: J Clin Endocrinol Metab Date: 2021-03-25 Impact factor: 5.958
Authors: Peter J Snyder; Jessica Alber; Clemens Alt; Lisa J Bain; Brett E Bouma; Femke H Bouwman; Delia Cabrera DeBuc; Melanie C W Campbell; Maria C Carrillo; Emily Y Chew; M Francesca Cordeiro; Michael R Dueñas; Brian M Fernández; Maya Koronyo-Hamaoui; Chiara La Morgia; Roxana O' Carare; Srinivas R Sadda; Peter van Wijngaarden; Heather M Snyder Journal: Alzheimers Dement Date: 2020-10-08 Impact factor: 21.566